Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment

Lung injury and STAT1 deficit induce EGFR overexpression in SARS-CoV-2 infection. A phase I/II trial was done to evaluate the safety and preliminary effect of nimotuzumab, an anti-EGFR antibody, in COVID-19 patients. Patients received from one to three infusions together with other drugs included in...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Immunotherapy 2022-05, Vol.14 (7), p.521-530
Hauptverfasser:	Londres, Henrry Diaz, Armada, Jorge Jiménez, Martínez, Aray Hernández, Abdo Cuza, Anselmo A, Sánchez, Yamilka Hernández, Rodríguez, Aylin Granado, Figueroa, Sarahy Sepúlveda, Llanez Gregorich, Egda M, Torres Lahera, Mery L, Peire, Francisco Gómez, González, Teresita Montero, González, Yaneth Zamora, Añé Kouri, Ana L, Palomo, Addys González, Concepción, Mayelin Troche, Pérez, Loipa Medel, Luaces-Alvarez, Patricia Lorenzo, Iglesias, Daymys Estévez, Hernández, Danay Saavedra, Suzarte, Mayra Ramos, Ramos, Tania Crombet
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - adverse effects COVID-19 COVID-19 - drug therapy EGFR ErbB Receptors Fibrosis Humans inflammation Middle Aged monoclonal antibody nimotuzumab Preliminary Communication SARS-CoV-2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!